How to Use the Wegovy 0.5mg Pen: What the Evidence Says About This Dose

Why the titration schedule matters at 0.5mg

Semaglutide's clinical programme was designed with a slow dose escalation from the start. The STEP 1 trial (published in the New England Journal of Medicine) ran participants through a 16-week ramp before reaching the 2.4mg maintenance dose, and the tolerability data from that programme shaped the schedule now written into the Wegovy licence. The 0.25mg pen is a settling-in dose; it has no therapeutic weight-loss target of its own. The 0.5mg pen is where the schedule begins its real climb.

That distinction matters practically. Some people feel a noticeable shift in appetite around the second or third injection at 0.5mg. Others notice little change from the starting pen. Both are normal. The prescriber who reviewed your consultation is the right person to contact if you're unsure whether what you're experiencing is typical, not a forum, not a dosing chart you found online.

If you want to understand the full dose arc from 0.25mg through to the higher maintenance doses, the Wegovy doses guide sets out the licensed schedule clearly.

Exactly how to inject the 0.5mg pen

The injection method is the same regardless of which Wegovy pen strength you're using. Choose one of three sites: abdomen (at least 5cm from the navel), front of the thigh, or outer upper arm. Rotate your site each week, using the same spot repeatedly can cause skin changes that affect how the medicine is absorbed.

Before you inject, check the solution in the pen window. It should be clear and colourless; don't use it if it looks cloudy or contains particles. Remove the cap, press the pen firmly against clean skin, and activate the injection button. Hold it in place until the flow indicator confirms the dose is complete, the leaflet that came in your box shows exactly what to look for on your specific device. The Wegovy multi-dose pen guide has more detail on reading the injection window if you're unsure.

One practical note on timing: your injection day is worth anchoring to something fixed, a Monday, a payday, a regular evening routine. Missing a dose by more than five days means skipping it entirely and resuming on your next scheduled day. Your Patient Information Leaflet covers missed-dose guidance in full; never adjust your schedule without checking it first.

Used needles and pens go in a sharps container, not the household bin. Your local pharmacy or GP surgery can advise on disposal collection in your area.

Side effects that show up most at the 0.5mg step, and what to do

The most common side effects with semaglutide are gastrointestinal: nausea, vomiting, diarrhoea, constipation, reflux and burping appear in the prescribing data and in real-world use. They tend to peak in the first week after a dose increase and settle over the following one to two weeks as the body adjusts. At 0.5mg (a relatively modest step) many people find the GI burden lighter than they expected, though individual responses vary considerably.

The MHRA asks patients and prescribers to report suspected side effects via the Yellow Card scheme. If something feels serious (severe or persistent stomach pain that radiates to the back, signs of an allergic reaction, or significant dehydration from repeated vomiting) get medical help promptly rather than waiting for your next check-in. These are not signals to manage at home.

Eating smaller portions, choosing lower-fat meals and staying well hydrated can reduce GI discomfort at this dose. Protein and fibre become more important as appetite falls; your prescriber or a dietitian can help you build a practical eating pattern alongside treatment. The Wegovy overview has more on what to expect across the full course of treatment.

Storage, eligibility and what comes next on the schedule

Store the 0.5mg pen in the fridge at 2–8°C, away from the freezer compartment. If you need to travel with it, the Patient Information Leaflet in your box states the exact room-temperature storage window, follow that, not general advice you've read elsewhere, because the limit is precise.

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. That's the licensed eligibility; a prescriber assesses whether those criteria apply to you individually, and whether the 0.5mg step is the right place for you in the schedule at any given point.

For private treatment, how Wegovy is priced in the UK is worth understanding before you start, costs vary by provider, and what's included in the headline price differs more than most people realise. On the NHS, access is via specialist weight management services and waiting lists are commonly lengthy; the weight-loss treatment overview explains both routes plainly.

After four weeks at 0.5mg, the standard next step is 1mg. If you'd like to read ahead, the guide to the 1mg pen covers what changes at that dose and what stays the same. The step after that is 1.7mg, then 2.4mg, and for those who need it, the four-dose pen format at higher strengths is worth understanding before you get there.

If you're just starting out and want to check whether Wegovy is clinically suitable for you, check your eligibility with our prescribers, the consultation is free and reviewed the same day by a real clinician.